On behalf of the Bliss Family and International Waldenstrom Macroglobulinemia Foundation (IWMF), we are pleased to announce the Bliss Family Fund to Advance Cellular Therapies for WM – a Request for Proposal (RFP).

Under this Grant program, the Bliss Family and IWMF seek to support independent investigators affiliated with academic institutions in conducting investigator-initiated trials (IITs) of cellular immunotherapies and related immune-redirection strategies with potential to significantly advance the treatment of WM. Importantly, the Bliss Family and IWMF are seeking distinctly novel advances and highly innovative approaches.

Applications are invited for clinical studies evaluating novel cellular or immune-engaging therapeutic approaches for WM, including but not limited to autologous or allogeneic cell therapies, CAR-T or CAR-NK platforms, bispecific and trispecific immune engagers, dual-target or next-generation engineered cellular approaches, rational immune-based combination therapies, or other highly innovative immunotherapeutic strategies with strong scientific and clinical rationale for WM.

Amount: up to $1,000,000 USD

Duration: 3-5 years

RFP Due: October 26, 2026

Working in partnership with our world-class Scientific Advisory Committee, IWMF has developed a Strategic Research Agenda to advance innovative discoveries, support novel clinical trials, and foster collaborations that will continue to revolutionize treatments for WM.

• • Acceleration and Expansion Research Grants
  • Correlative Companion Research Grants
  • Pilot Clinical Trial Grants
  • Robert A. Kyle Career Development Award Grant
  • Translational Research Grants